About TrovaGene (NASDAQ:TROV)
Trovagene, Inc. (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. It has ongoing clinical collaborations to demonstrate the ability to determine and monitor mutational status and response to therapy in lung, colon, pancreatic and skin cancer. It uses its molecular diagnostic technology for the detection of cell-free deoxyribonucleic acid (DNA) originating from diseased cell death that can be isolated and detected from urine, blood and tissue samples to develop disease management.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Diagnostic & Testing Substances
- Sub-Industry: N/A
- Symbol: NASDAQ:TROV
- CUSIP: N/A
- Web: www.trovagene.com
- Market Cap: $30.67 million
- Outstanding Shares: 37,269,000
- 50 Day Moving Avg: $0.74
- 200 Day Moving Avg: $0.87
- 52 Week Range: $0.61 - $4.25
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: 0.000
- Annual Revenue: $354,234.00
- Price / Sales: 84.69
- Book Value: $0.11 per share
- Price / Book: 7.12
- EBITDA: ($29,350,000.00)
- Net Margins: -10,390.96%
- Return on Equity: -201.07%
- Return on Assets: -85.12%
- Current Ratio: 1.16%
- Quick Ratio: 1.16%
- Average Volume: 625,514 shs.
- Beta: 0.3
- Short Ratio: 3.74
Frequently Asked Questions for TrovaGene (NASDAQ:TROV)
What is TrovaGene's stock symbol?
TrovaGene trades on the NASDAQ under the ticker symbol "TROV."
How were TrovaGene's earnings last quarter?
TrovaGene, Inc. (NASDAQ:TROV) announced its earnings results on Tuesday, May, 10th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.29) by $0.07. The company earned $0.12 million during the quarter, compared to analysts' expectations of $0.34 million. TrovaGene had a negative net margin of 10,390.96% and a negative return on equity of 201.07%. View TrovaGene's Earnings History.
When will TrovaGene make its next earnings announcement?
Where is TrovaGene's stock going? Where will TrovaGene's stock price be in 2017?
3 brokerages have issued 1 year target prices for TrovaGene's stock. Their forecasts range from $1.80 to $8.00. On average, they expect TrovaGene's share price to reach $4.60 in the next year. View Analyst Ratings for TrovaGene.
What are analysts saying about TrovaGene stock?
Here are some recent quotes from research analysts about TrovaGene stock:
- 1. Maxim Group analysts commented, "Trovagene announced positive preclinical data for PCM-075, an oral polo-like kinase 1 (PLK1) inhibitor demonstrating synergy (80%) with a histone deacetylase (HDAC) inhibitor in aggressive double-hit non-Hodgkin lymphoma (NHL). B-cell lymphoma has the highest fold overexpression of PLK1 (56X)." (8/22/2017)
- 2. Cantor Fitzgerald analysts commented, "The partnership with Boreal Genomics is an important milestone for the company, in our view. Per the long-term supply and distribution agreement, 1) TROV commits upfront and milestone payments totaling $1M, 2) TROV has global distribution rights in blood and exclusively in urine for least ten years, and 3) TROV and Boreal will form a joint effort to bring the assay kits and systems through the necessary regulatory pathways for approval. Importantly, TROV continues to target the analytical validation of its initial panel by the end of 2016 and plans to launch a series of cancer-specific multigene ctDNA urine and blood panels, in partnership with Boreal, in 2017. For more details on TROV’s commercialization strategy, please see our September 30, 2016 note. The OnTarget platform separates target mutations from the wild-type. In a one-hour process, the sample is injected into a gel matrix containing short oligo probes that are complementary to the target mutations. The temperature is increased to the melting temperature of the target-probe duplex and target mutations are separated by repeated hybridization in an alternating electric field. Target alleles are collected in the extraction chamber, while the wild-type is removed with more than 1M fold enrichment (and as high as 10M fold)." (11/30/2016)
Who are some of TrovaGene's key competitors?
Some companies that are related to TrovaGene include The Joint Corp. (JYNT), Chiasma (CHMA), Cardiome Pharma Corporation (CRME), CytRx Corporation (CYTR), Flex Pharma (FLKS), Xenon Pharmaceuticals (XENE), Catasys (CATS), Alphatec Holdings (ATEC), ContraVir Pharmaceuticals (CTRV), KemPharm (KMPH), Proteostasis Therapeutics (PTI), OvaScience (OVAS), Cancer Genetics (CGIX), Akari Therapeutics PLC (AKTX), Leap Therapeutics (LPTX), Evoke Pharma (EVOK), Prima BioMed Ltd (PBMD) and IntelGenx Technologies Corp. (IGXT).
Who are TrovaGene's key executives?
TrovaGene's management team includes the folowing people:
- Thomas H. Adams Jr. Ph.D., Chairman of the Board
- William J. Welch, Chief Executive Officer, Director
- Athena M. Countouriotis M.D., Director
- Paul R. Billings M.D., Ph.D., Independent Director
- John P. Brancaccio CPA, Independent Director
- Gary S. Jacob Ph.D., Independent Director
- Rodney S. Markin M.D., Ph.D., Independent Director
Who owns TrovaGene stock?
TrovaGene's stock is owned by many different of retail and institutional investors. Top institutional shareholders include
CVI INVESTMENTS, INC.
(5.70%). Company insiders that own TrovaGene stock include Mark Erlander, Stanley Tennant and William J Welch. View Institutional Ownership Trends for TrovaGene.
How do I buy TrovaGene stock?
Shares of TrovaGene can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is TrovaGene's stock price today?
MarketBeat Community Rating for TrovaGene (NASDAQ TROV)MarketBeat's community ratings are surveys of what our community members think about TrovaGene and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of TrovaGene stock can currently be purchased for approximately $0.81.
Consensus Ratings for TrovaGene (NASDAQ:TROV) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Sell Rating, 2 Buy Ratings|
|Consensus Rating:||Hold (Score: 2.33)|
|Consensus Price Target: ||$4.60 (471.43% upside)|Consensus Price Target History for TrovaGene (NASDAQ:TROV)
Analysts' Ratings History for TrovaGene (NASDAQ:TROV)
(Data available from 10/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/18/2017||Maxim Group||Set Price Target||Buy||$4.00||N/A|
|8/8/2017||Cantor Fitzgerald||Reiterated Rating||Overweight||High|
|3/16/2017||Piper Jaffray Companies||Downgrade||Neutral -> Underweight||High|
|3/10/2017||S&P Equity Research||Boost Price Target||$1.55 -> $1.80||N/A|
|5/12/2016||Leerink Swann||Reiterated Rating||Hold||N/A|
|4/28/2016||Argus||Downgrade||Buy -> Hold||N/A|
|3/29/2016||Avondale Partners||Reiterated Rating||Market Perform||$6.00||N/A|
|3/11/2016||Janney Montgomery Scott||Downgrade||Buy -> Neutral||N/A|
|2/22/2016||Jefferies Group LLC||Reiterated Rating||Buy||N/A|
Earnings History for TrovaGene (NASDAQ:TROV)Earnings History by Quarter for TrovaGene (NASDAQ TROV)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/10/2016||Q116||($0.29)||($0.36)||$0.34 million||$0.12 million||View||Listen|
|3/10/2016||Q415||($0.25)||($0.26)||$0.14 million||$0.08 million||View||Listen|
|5/5/2015||($0.23)||($0.24)||$0.08 million||$0.13 million||View||N/A|
|11/6/2014||Q3 14||($0.25)||($0.28)||$0.05 million||$0.06 million||View||N/A|
|8/7/2014||($0.24)||($0.18)||$0.05 million||$0.06 million||View||N/A|
|5/12/2014||($0.23)||($0.17)||$0.05 million||$0.11 million||View||N/A|
|3/17/2014||Q413||($0.19)||($0.05)||$0.15 million||$0.05 million||View||N/A|
|5/14/2013||Q113||($0.09)||($0.07)||$0.03 million||$0.12 million||View||N/A|
Earnings Estimates for TrovaGene (NASDAQ:TROV)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for TrovaGene (NASDAQ:TROV)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for TrovaGene (NASDAQ:TROV)
Insider Ownership Percentage: 7.40%Insider Trades by Quarter for TrovaGene (NASDAQ:TROV)
Institutional Ownership Percentage: 8.94%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/5/2017||Stanley Tennant||Director||Sell||8,334||$0.69||$5,750.46|| |
|12/19/2016||Stanley Tennant||Director||Buy||10,000||$2.10||$21,000.00|| |
|12/16/2016||Stanley Tennant||Director||Buy||14,966||$2.00||$29,932.00|| |
|12/16/2016||William J Welch||CEO||Buy||4,750||$2.09||$9,927.50|| |
|12/14/2016||Mark Erlander||Insider||Buy||5,000||$2.08||$10,400.00|| |
|8/12/2015||Antonius Schuh||CEO||Buy||20,000||$5.45||$109,000.00|| |
|8/12/2015||Stanley Tennant||Director||Buy||10,000||$6.06||$60,600.00|| |
|8/12/2015||Steve Zaniboni||CFO||Buy||15,000||$5.43||$81,450.00|| |
|7/17/2015||Bridger Management, Llc||Major Shareholder||Buy||140,000||$8.75||$1,225,000.00|| |
|4/2/2015||Bridger Management, Llc||Major Shareholder||Buy||300,000||$6.90||$2,070,000.00|| |
|2/27/2015||Bridger Management, Llc||Major Shareholder||Buy||263,286||$5.36||$1,411,212.96|| |
|2/6/2015||Bridger Management, Llc||Major Shareholder||Buy||444,444||$4.50||$1,999,998.00|| |
|6/9/2014||Steve Zaniboni||CFO||Buy||6,329||$3.95||$24,999.55|| |
|9/3/2013||Thomas Phd Adams||Director||Sell||19,200||$8.19||$157,248.00|| |
|11/30/2012||Stanley Tennant||Director||Buy||25,000||$4.82||$120,500.00|| |
|8/20/2012||Gabriel Cerrone||Director||Buy||7,800||$2.35||$18,330.00|| |
|8/16/2012||Gabriel Cerrone||Director||Buy||15,000||$2.24||$33,600.00|| |
Headline Trends for TrovaGene (NASDAQ:TROV)
Latest Headlines for TrovaGene (NASDAQ:TROV)
Loading headlines, please wait.
TrovaGene (TROV) Chart for Sunday, October, 22, 2017